Actively Recruiting
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
Led by Umeå University · Updated on 2024-02-28
420
Participants Needed
1
Research Sites
517 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
CONDITIONS
Official Title
Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Histologically confirmed prostate cancer
- Indication for early palliative radiotherapy for low burden metastatic prostate cancer, defined by modified CHAARTED criteria as having a maximum of 4 skeletal metastases at any site and/or any number of lymph node metastases
- Baseline electronic patient-reported outcome measurement (E-PROM)
You will not qualify if you...
- High burden metastatic prostate cancer including any visceral metastases
- Inability to comply with study procedures
- Other diseases or medications increasing risk of radiotherapy toxicity
- Radiotherapy starting more than nine months after prostate cancer diagnosis
- Severe urinary problems with an International Prostate Symptom Score greater than 20
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancercenter University hospital of Umeå
Umeå, Sweden, 90596
Actively Recruiting
Research Team
C
Camilla Thellenberg Karlsson, MD, PhD
CONTACT
K
Karin Söderkvist, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here